Pinealon Peptide: Benefits & Dosage

You are probably trying to decode the name and the abbreviation on the vial. Pinealon is a synthetic three-amino-acid peptide: glutamic acid, aspartic acid, and arginine. The literature writes the sequence as Glu-Asp-Arg and shortens it to EDR. The "pineal" in the name points to its origin story, because early work tied the molecule to brain and pineal-gland regulation rather than to a single hormone.

Russian researchers at the Saint Petersburg Institute of Bioregulation and Gerontology developed it, the same group behind a family of short peptides aimed at specific organs. The lead scientist was Professor Vladimir Khavinson, a gerontologist who argued for decades that short peptides can "tune up" the tissue they are addressed to (Khavinson VK, Neuroendocrinology Letters, 2002). Pinealon came out of the brain and neuroprotection side of that program.

The same lab built peptides for other tissues. One for the heart, one for the thymus, one for the pineal gland. Epitalon is the better-known pineal peptide from the same group, and Pinealon is often discussed alongside it for brain aging. For the pineal sibling, see the Epitalon profile, and for how the bioregulator class works in the heart, see Cardiogen peptide benefits.

Regulatory status is worth pinning down before you spend money. In the United States, Pinealon has no FDA approval for any medical use, and vials are sold strictly for laboratory research. It is not a prescribed drug and not a dietary supplement. For storing the lyophilized powder and the mixed solution correctly, see how to store peptides.

Picture a circuit breaker panel inside each neuron, with switches that control which genes run and how the cell handles stress. The bioregulator theory says short peptides act like a technician who flips a few specific breakers back to the "young" position. Pinealon is supposed to be the technician assigned to brain cells.

That picture rests on a handful of specific claims, and you should weigh each one.

Claim one: it reaches the cell nucleus and touches gene expression. The Russian model says EDR slips into neurons, enters the nucleus, and interacts with stretches of DNA near gene switches. Khavinson's group reported that short peptides like EDR can bind specific DNA sequences and change the activity of genes tied to neuron survival (Khavinson VK, Lin'kova NS, et al., Bulletin of Experimental Biology and Medicine, 2011).

Claim two: it protects neurons under oxidative and hypoxic stress. In cell-culture work, EDR was reported to reduce neuron death when cells were exposed to hydrogen peroxide or to low-oxygen conditions, with lower markers of programmed cell death (Chalisova NI, et al., reported in Russian neuropeptide studies). The proposed route is steadier antioxidant defenses and calcium handling inside the cell.

Claim three: tiny doses, short cycles. Because the peptide is described as a signal rather than a drug substitute, research protocols use microgram-to-milligram amounts for a couple of weeks at a time, then stop. The logic is that once the gene-expression pattern is nudged, you let the tissue run on the new pattern.

Here is the catch. A peptide this small usually breaks apart in blood within minutes and has a hard time getting into cells, let alone reaching the nucleus and finding a specific DNA sequence. Western pharmacologists look at the DNA-binding claim and ask for extraordinary proof. Russian labs report the results. Independent labs outside that network have not reproduced them with modern genomic tools. For the related nootropic peptides studied in the same tradition, see Selank and Semax.

You probably want a plain list of what this peptide is supposed to do. Almost every claim below comes from Russian in vitro and rodent studies. The work is preclinical, the human data is sparse, and nothing here meets the bar a Western regulator would require. Read the list as "here is what the literature reports," not "here is what science has proven."

Neuron protection under oxygen starvation. The headline finding is neuroprotection. In rat models of prenatal and postnatal hypoxia, EDR was reported to improve neuron survival and learning behavior compared to untreated animals (Khavinson VK, et al., Bulletin of Experimental Biology and Medicine, 2012). The proposed mechanism is lower oxidative damage inside the cell.

Antioxidant support inside brain cells. Cell-culture studies reported reduced markers of oxidative stress and fewer apoptotic neurons after EDR exposure. The authors framed this as the peptide helping cells weather damage rather than acting as a stimulant.

Possible memory and learning effects in animals. Rodent maze studies reported modest improvements in learning and memory retention after EDR dosing. These are animal behavior measures, not validated human cognition trials. If your interest is human cognitive performance, read our broader cognitive function guide for context on what is actually evidenced.

Circadian and sleep-clock support. Because the molecule sits in the pineal-related research line, some work proposes effects on the sleep-wake rhythm in aging animals. The evidence here is thin and indirect. For the human side of this question, see peptides for sleep.

Used inside an anti-aging stack. Russian researchers often discuss Pinealon alongside Epitalon and immune peptides on the theory that brain, pineal, and immune systems age together. For the pineal sibling, see the Epitalon profile, and for an immune bioregulator with stronger Western data, see thymosin alpha-1 benefits.

What Pinealon is not. It is not a proven treatment for dementia, stroke recovery, or any neurological disease. No approved drug indication exists. If you have a diagnosed condition, your prescribed care stays put, and Pinealon is at best an experimental add-on you discuss with a physician.

If you are deciding whether to spend money on this peptide, the most useful thing you can know is the quality of the data. Treat this section like a credit report on the evidence.

Cell and animal studies. Moderate volume, single network. Khavinson's group and a few allied Russian labs have published in vitro work on cultured neurons and in vivo work in rodents, reporting neuroprotection, lower oxidative stress, and behavioral gains. Some of these papers sit in PubMed-indexed journals such as Bulletin of Experimental Biology and Medicine and Molecular Biology (Lin'kova NS, et al., Molecular Biology, 2016).

Human clinical trials. Essentially absent. There are no large, randomized, placebo-controlled human trials of Pinealon. What exists is small, mostly uncontrolled clinical observation reported by the originating institute. You cannot point to a Phase II or Phase III dataset because none has been published.

Replication outside the original network. Almost none. The EDR-specific literature is dominated by Saint Petersburg. In mainstream pharmacology, a mechanism that only one network of labs can demonstrate is treated as provisional, no matter how interesting it reads.

Mechanistic plausibility. Mixed. The proposed DNA-binding mechanism would rewrite parts of peptide pharmacology if confirmed. Simpler explanations, such as a general antioxidant metabolite effect, have not been systematically ruled in or out by independent labs.

Funding and publication bias. Most Pinealon research is funded by Russian state programs or by the institute connected to the peptide's development. That is common for a young compound, but it means the literature is not a disinterested source.

Here is what this means for you. The rodent and cell-culture findings may or may not translate to a person. Pinealon may help, it may work through a different route than its developers describe, or it may do nothing measurable in humans. Some practitioners look at the low reported harm signal and treat it as a low-stakes personal experiment. That is a defensible choice made with clear eyes. It is not evidence-based medicine. For peptides with stronger Western backing in the same broad space, see thymosin alpha-1 benefits and the nootropic Semax profile.

Now you are looking at the vial and trying to figure out how it has been dosed in studies. Important caveat first. These are commonly reported research protocols, not clinically established human doses. No regulator has validated a Pinealon dose for any human use, and the vial is sold for research only.

Commonly reported subcutaneous protocol: - Dose: 100 mcg to a few milligrams per administration in reported animal and exploratory work - Frequency: Once daily - Duration: 10 to 20 consecutive days per cycle - Repetition: Cycles spaced months apart, mirroring the bioregulator cycling logic

Intranasal route. Some neuropeptide research uses the nasal route to favor brain delivery, and a few EDR studies report intranasal administration. This route is experimental and not standardized for Pinealon.

Reconstitution. Pinealon ships as a lyophilized powder you mix with bacteriostatic water before subcutaneous use. Getting the concentration right matters because the doses are small. Run the numbers with the peptide reconstitution calculator so you know how many units on the syringe equal your intended microgram dose.

Injection basics. If you have never injected a subcutaneous peptide, read how to inject peptides before you handle a syringe, and check how long reconstituted peptides last so you do not use a vial past its window.

Why the cycles? The bioregulator model argues that once gene expression is nudged, continuous dosing is unnecessary and may even dull the response. That logic is the opposite of how most drugs work, where you hold blood levels steady. Whether the cycling logic is correct depends on whether the underlying mechanism story is correct, and that has not been independently confirmed. For a general dosing framework across mainstream peptides, see the peptide dosage chart.

If you are weighing Pinealon against its neighbors, a side-by-side helps. None of these peptides is FDA-approved for cognitive or neurological use, and the evidence quality varies a lot.

Pinealon vs Epitalon. Epitalon (Ala-Glu-Asp-Gly) is the better-known pineal peptide from the same Khavinson program, studied mostly for telomere and aging endpoints rather than acute neuroprotection. The two are often cycled together in anti-aging discussions, and both share the same thin, Russian-dominated evidence base. See the Epitalon profile for the full picture.

Pinealon vs Selank. Selank is a synthetic analog of a natural peptide, studied in Russia for anxiety and cognition, with a somewhat larger clinical literature than Pinealon. It targets mood and stress circuits rather than neuron survival under hypoxia. See the Selank profile.

Pinealon vs Semax. Semax is another Russian neuropeptide, used clinically there for stroke and cognitive complaints, with more human exposure data than Pinealon. It is closer to a nootropic with documented use, while Pinealon remains preclinical. See the Semax profile and our cognitive function guide.

Pinealon vs Cardiogen. Cardiogen is the heart-targeted member of the same bioregulator family. Same lab, same cycling logic, same evidence problem, different target tissue. See Cardiogen peptide benefits.

Pinealon vs proven cognitive care. This is not a real comparison. For diagnosed neurological disease, validated treatments and lifestyle factors (sleep, exercise, blood pressure and lipid control) have far more evidence than any research peptide. Pinealon, if you use it, is an experiment layered on top of that foundation, never a replacement for it. For sleep specifically, see peptides for sleep.

You are about to handle something the FDA has never reviewed. The reported safety signal is mild in the small studies that exist, but the gaps are large and you should know exactly where they are.

What the studies report. Side effects in the published EDR work are rare and mild, with no serious adverse event clearly attributed to the peptide. That signal sits on a tiny database with short follow-up and almost no human exposure, so do not read it as proof of long-term safety.

Who should not use Pinealon at all. - Pregnant or breastfeeding people: no safety data - People with active cancer: theoretical concern because the proposed mechanism touches gene regulation - Anyone under 18: no safety data - Anyone with a neurological diagnosis who has not cleared it with their physician

Common mistakes that cause real problems:

Mistake one: dosing by eye instead of by math. Because the active amounts are microgram-scale, a small misread on the syringe can swing your dose several-fold. If a protocol calls for 100 mcg and you draw what you think is "a little," you can land at 300 to 500 mcg without noticing. Fix it by calculating the exact unit mark with the peptide reconstitution calculator before you draw.

Mistake two: using a vial that has sat too long. Reconstituted peptide degrades. Inject from a vial that has been in the fridge for six weeks and you may be dosing a fraction of the intended amount, then wrongly conclude the peptide "does nothing." Fix it by tracking the mix date and following how long reconstituted peptides last.

Mistake three: storing the powder wrong. Lyophilized peptide left warm or in light loses potency before you ever reconstitute it. Fix it by following how to store peptides from the day the vial arrives.

The biggest practical risk: counterfeit or impure product. Because Pinealon is sold through research-chemical channels with little third-party testing, the vial may not contain what the label claims. For another antimicrobial-adjacent peptide where sourcing and purity matter just as much, see LL-37 benefits. Any new neurological symptom during use, such as severe headache, confusion, or numbness, is a stop signal that warrants a physician.